Sagard Healthcare closes $250 million permanent credit facility

Chicago, Jan. 4 – Sagard Healthcare announced that it closed on a $250 million revolving credit facility with a syndicate of lenders in December, according to a press release on Thursday.

The facility is expected to grow in size as Sagard expands its portfolio.

In turn, Sagard recently funded nearly $250 million of new royalty and credit investments, namely through a term loan to Phathom Pharmaceuticals and a royalty in Tyvaso DPI net sales from MannKind Corp. for up to $200 million.

The $300 million Phathom Pharmaceuticals term loan was funded with unnamed investment partners.

Sagard is a biopharmaceutical royalty and credit investor based in Toronto.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.